Recently, a study described that a novel TLR7 agonist reverted the suppressive tumor milieu leading to tumor cell killing by NK cells as well as T cells.26, 27 Moreover, topical application of imiquimod (the only TLR7 agonist approved by FDA) is used for treatment of nonmelanoma skin cancer and provide beneficial effects in melanoma patients.28, 29, 30 Indeed, we observed that additional treatment with imiquimod effectively delayed resistance development by shaping the effector T and NK cell immune landscape during BRAF‐targeted therapy. Here, BRAF is linked to neoplasm.